How should paroxysmal supraventricular tachycardia refractory to a 12 mg adenosine dose be managed?

Management of PSVT Refractory to 12 mg Adenosine

For hemodynamically unstable patients, proceed immediately to synchronized cardioversion; for hemodynamically stable patients, administer intravenous diltiazem or verapamil as the next-line therapy. 1

Hemodynamic Status Determines Next Step

The critical decision point after adenosine failure is the patient's hemodynamic stability:

Hemodynamically Unstable Patients

• Proceed directly to synchronized cardioversion 1
• This is a Class I recommendation with strong guideline support
• Cardioversion is highly effective in terminating SVT and avoids complications from additional antiarrhythmic drugs
• Unstable features include: hypotension, altered mental status, signs of shock, chest pain suggesting ischemia, or acute heart failure symptoms

Hemodynamically Stable Patients

Administer intravenous calcium channel blockers as second-line therapy:

• Diltiazem: 0.25 mg/kg IV bolus over 2 minutes 1

  • If no response, can start infusion at 5-10 mg/h (up to 15 mg/h)
  • Success rate: 64-98% for SVT termination 1

• Verapamil: 5-10 mg (0.075-0.15 mg/kg) IV bolus over 2 minutes 1

  • Can give additional dose if needed
  • Similar efficacy to diltiazem

• Alternative: Intravenous beta-blockers (esmolol, metoprolol, propranolol) 1

  • Class IIa recommendation (reasonable option)
  • Slightly less effective than calcium channel blockers but excellent safety profile
  • Esmolol: 500 mcg/kg IV bolus over 1 minute, then infusion at 50-300 mcg/kg/min

Critical Contraindications and Precautions

Do NOT use calcium channel blockers if:

• Pre-excited atrial fibrillation (WPW with AF) is suspected - can cause ventricular fibrillation 1
• Wide-complex tachycardia of uncertain etiology - may be ventricular tachycardia
• Known systolic heart failure or suspected ventricular dysfunction 1
• Hypotension at baseline

If any of these are present, proceed directly to cardioversion even in stable patients.

If Pharmacologic Therapy Fails

Synchronized cardioversion is recommended for stable patients when medications are ineffective or contraindicated 1

• Perform after adequate sedation/anesthesia in stable patients
• Success rate approaches 100% for SVT termination
• Most stable patients respond to pharmacologic therapy (80-98% success with verapamil, diltiazem, or adenosine), but cardioversion is definitive when drugs fail

Special Considerations for Adenosine Failure

While not standard practice, research suggests some patients may respond to higher adenosine doses (18 mg) 2, 3, 4:

• One study showed 18 mg adenosine achieved sinus rhythm in patients who failed 12 mg 3
• This may be particularly relevant in patients with impaired venous return (right heart failure, pulmonary hypertension) 2
• However, this is not guideline-recommended and should only be considered in select cases with appropriate monitoring

Factors associated with adenosine failure that may guide your approach 5, 6:

• History of heart failure (reduces success by 70%)
• Current antiarrhythmic drug use (reduces success by 68%)
• Lower ionized calcium levels
• These patients may benefit from proceeding directly to calcium channel blockers or cardioversion

Common Pitfalls to Avoid

1. Do not give amiodarone or digoxin for acute narrow-complex SVT - these are no longer recommended per 2019 ESC guidelines 7

2. Do not delay cardioversion in unstable patients to try additional medications

3. Always have cardioversion equipment ready when administering any antiarrhythmic, as adenosine can precipitate atrial fibrillation that may conduct rapidly 1, 8

4. Ensure proper adenosine administration technique - rapid IV push through proximal line with immediate saline flush. Failure may be technical rather than true refractoriness

5. Be prepared for recurrence - patients often have premature complexes after conversion that can reinitiate tachycardia, requiring additional antiarrhythmic therapy to prevent acute reinitiation 1